Robert W. Rubin, Ph.D.Chief Executive Officer
Shannon L. TomaExecutive Vice President, Chief Operating Officer
Steven Belinsky, PhDVice President for
Robert W. Rubin, Ph.D., Chief Executive Officer, has over 40 years of experience in research and development, including 21 years in his current role. He came to Lovelace after serving as Vice Provost for Research at the University of Miami. Under Dr. Rubin’s guidance, Lovelace transitioned from a Department of Energy-funded research facility to one of the country’s most preeminent drug development laboratories.
Shannon L. Toma, C.P.A., is Executive Vice President and chief operating officer. She is responsible for administrative operations, safety, regulatory, legal and financial compliance. In this role, she works closely with the CEO and senior management to develop and implement the company vision and mission via the strategic plan including new business, acquisitions and strategic partnerships.
University of North Carolina at Chapel Hill, B.S. 1978 Zoology
University of North Carolina at Chapel Hill, Ph.D. 1984 Toxicology
Dr. Belinsky is Vice President for Research, Director of the Lung Cancer Program, and co-directs the Cellular and Molecular Oncology Program for the University of New Mexico’s NCI designated Cancer Center. He has worked in the field of tobacco carcinogenesis for >30 years and is an internationally recognized expert in lung cancer and translational studies for early detection of lung cancer. His laboratory was first to demonstrate that tobacco specific nitrosamines cause DNA adducts that accumulate in the lung and lead to mutation of the K-ras oncogene and that silencing of the p16 tumor suppressor gene occurs during development of lung cancer. His current work evaluates epigenetic mechanisms for lung cancer, specifically inactivation of genes and microRNAs through promoter hypermethylation and chromatin remodeling. His research is focused on identifying gene targets and pathways disrupted during the development of this disease. These findings are translated into population-based studies to develop intermediate biomarkers for predicting cancer risk, early detection, prognosis, and response to preventive interventions. His group is using animal models to evaluate novel prevention and therapeutic approaches administered by inhalation to reduce the mortality from lung cancer. Recent new studies are assessing cardiopulmonary health effects of alternative nicotine containing products using in vitro and rodent models. Dr. Belinsky has authored more than 200 publications.
Ted Barrett, Ph.D., is Senior Director, Pharmacology at Lovelace Biomedical. Dr. Barrett has spent most of his career investigating the effects of small molecule, biologic, nucleic acid and medical device technologies in various animal models of disease. His programs aim to translate nonclinical efficacy, pharmacokinetic, and pharmacodynamic data obtained by from species ranging from rodents to nonhuman primates to the human clinical paradigm. Dr. Barrett received his doctorate in toxicology from the University of Rochester and joined Lovelace in 1999.
Philip Kuehl, Ph.D., is a senior scientist and head of the Scientific Core Laboratories at Lovelace Biomedical. The Scientific Core Laboratories are responsible for the formulation, chemistry, bioanalysis, aerosol engineering solutions, microbial analysis and telemetry systems. Dr. Kuehl is an expert in non-clinical drug development with experience in the design, conduct and regulatory approach for translational drug development with a focus in inhalation and gene therapy. Dr. Kuehl is renowned for his contributions to pulmonary formulation, understanding dose to the lung, translating non-clinical to clinical dose and respiratory drug development. He has over 80 publications in translational drug development, serves as the General Secretary of the International Society for Aerosols in Medicine, is on the editorial board of Journal of Aerosol Medicine and Pulmonary Drug Delivery and AAPS PharmSciTec and is an ad hoc reviewer of numerous journals. Dr. Kuehl received his B.A. in biochemistry from Hamline University in St. Paul, Minnesota and a Ph.D. in pharmaceutical sciences (minor in analytical chemistry) from the University of Arizona. Dr. Kuehl joined Lovelace in 2007.
Theodore (Ted) W. Sanders Jr., D.V.M., M.S., M.B.A., D.A.C.L.A.M., is Lovelace’s Director Comparative Medicine and Attending Veterinarian and is responsible for both the strategic and operational activities of the Institute’s animal research program. He provides guidance and leadership for veterinary services, research support, husbandry, pharmacy, study scheduling, client support and related administrative teams.
He has over 33 years of experience supporting all aspects of animal research operations. Before joining Lovelace he served with Pfizer and Zoetis where he served as the Vice President for Animal Care and Welfare. He also worked at Inotiv where he served as Senior Director for Laboratory Animal Resources, Regional- North America. He earned his Doctor of Veterinary Medicine degree from Louisiana State University, School of Veterinary Medicine. He earned his Master of Science degree in Biomedical Sciences from the Medical University of South Carolina where he also completed a residency in Laboratory Animal Medicine. He is a Diplomate of the American College of Laboratory Animal Medicine and earned a Master of Business Administration degree from the Eli Broad Graduate School of Management, Michigan State University. Ted joined Lovelace in 2023.
Nandakumar Ranganathan, is the Senior Director for Information Technology Solutions at Lovelace Biomedical. He has more than 25+ years of experience in Information Technology field. He is responsible for the management, strategy and execution of IT infrastructure. Prior to joining Lovelace he held leadership roles in Information Technology with State of New Mexico. Nanda joined in 2018.
Dale Mack, is the Senior Director of Facilities Operations and Radiation Safety Officer at Lovelace Biomedical.
In addition to leading the operational and strategic Facilities and Engineering initiatives for Lovelace, he also overseas Biosafety, Environmental Health and Safety and Radiation Safety Management functions for Lovelace.
Prior to joining Lovelace, he held leadership roles at the Atlanta University Center Consortium, Morehouse School of Medicine and Theragenics Corporation.
He has over two decades of leadership experience, supporting research, development, operations, safety and regulatory, compliance in Academic Research, Academic Medical Center Operations and Medical Device Manufacturing.
He served as a Subject Matter Expert for the U.S. Environmental Protection Agency (EPA) Region 4, U.S. Department of Energy (DOE), National Nuclear Security Administration (NNSA) and the Federal Bureau of Investigation (FBI), Weapons of Mass Destruction Directorate (WMDD).
He holds a Bachelors of Science in Chemistry from Morehouse College. Dale joined Lovelace in 2015.
David Flanders is the Vice President of Human Resources at Lovelace Biomedical. In addition to leading the operational and strategic Human Resources initiatives for Lovelace, he also oversees the Security and Risk Management functions for the Institute. Prior to joining Lovelace he held leadership roles in Human Resources at The Scripps Research Institute and Sanford-Burnham-Prebys Medical Discovery Institute and has nearly two decades of Human Resources experience in non-profit biomedical research.
He holds a Master's of Science in Human Resources Management from the University of Southern California and a Bachelors of Business Administration in Management from Kennesaw State University. David joined Lovelace in 2015.